EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Rescue of loss‐of‐function long QT syndrome‐associated mutations in K V 7.1/KCNE1 by the endocannabinoid N‐arachidonoyl‐L‐serine (ARA‐S)

Irene Hiniesto-Iñigo, Akshay Sridhar, Julien Louradour iD, Alicia De la Cruz, Siri Lundholm, Amaia Jauregi-Miguel, Federica Giannetti iD, Luca Sala iD, Katja E Odening iD, H Peter Larsson iD, Nina E Ottosson iD, Sara I Liin iD

British Journal of Pharmacology · 2025

DOI: 10.1111/bph.70008 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Pharmacology, 2025. Verfasst von Irene Hiniesto-Iñigo und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden. Hauptthemen laut MEDLINE: Long QT Syndrome, KCNQ1 Potassium Channel, Potassium Channels, Voltage-Gated, Endocannabinoids. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Vetenskapsrådet, National Institutes of Health, National Heart, Lung, and Blood Institute, Konung Gustaf V:s and Drottning Victorias Stiftelse.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose Congenital long QT syndrome (LQTS) involves genetic mutations affecting ion channels, leading to a prolonged QT interval and increased risk of potentially lethal ventricular arrhythmias. Mutations in the genes encoding K V 7.1/KCNE1 are the most frequent, with channel loss‐of‐function contributing to LQTS. The endocannabinoid N‐arachidonoyl‐L‐serine (ARA‐S) has been shown to facilitate activation of wild type K V 7.1/KCNE1 channels and to counteract a prolonged QT interval in isolated guinea pig hearts. In this study, we examine the ability of ARA‐S to facilitate activation of LQTS‐associated mutations, in various regions of the channel, and hence to counteract loss‐of‐function. Experimental Approach The two‐electrode voltage clamp technique on Xenopus oocytes expressing human K V 7.1/KCNE1 channels was used to investigate the effects of ARA‐S in 20 LQTS type 1‐associated mutations distributed across the channel. Thereafter, different electrophysiology was used to assess ARA‐S effects in mammalian cells. Key Results ARA‐S enhanced the function of all mutated channels by shifting V 50 and increasing current amplitude. However, the magnitude of effect varied, related to whether mutations were in one of the two putative ARA‐S binding sites on the channel as suggested by molecular dynamics simulations. ARA‐S displayed translational potential by facilitating channel opening in mammalian cells and shortening the action potential duration in cardiomyocytes. Conclusions and Implications This study demonstrates the rescuing capability of ARA‐S on a diverse set of LQTS mutants. These insights may aid in developing drug compounds using ARA‐S sites and mechanisms and guide interpretation of which LQTS mutants respond well to such compounds.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Long QT SyndromeKCNQ1 Potassium ChannelPotassium Channels, Voltage-GatedEndocannabinoidsSerineArachidonic AcidsAnimalsHumansXenopus laevisMutationLoss of Function MutationOocytesFemaleHEK293 Cells

Stichwörter der Autor:innen

KCNQ1Kv7arrhythmiaelectrophysiologymolecular dynamics

Substanzen

KCNQ1 Potassium ChannelPotassium Channels, Voltage-GatedEndocannabinoidsSerineKCNE1 protein, humanArachidonic AcidsKCNQ1 protein, human

Autor:innen und Institutionen

  • Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.
  • Translational Cardiology, Department of Physiology and Department of Cardiology, University of Bern, University Hospital Bern, Bern, Switzerland.
  • Chemical Biology Consortium Sweden (CBCS), SciLifeLab, Stockholm, Sweden.
  • Istituto Auxologico Italiano IRCCS, Center for Cardiac Arrhythmias of Genetic Origin and Laboratory of Cardiovascular Genetics, Milan, Italy.
  • Department of Biotechnology and Biosciences, University of Milano-Bicocca, Milan, Italy.

ORCID-Profile: Julien Louradour, Federica Giannetti, Luca Sala, Katja E Odening, H Peter Larsson, Nina E Ottosson, Sara I Liin

Förderung

  • Vetenskapsrådet
  • National Institutes of Health, National Heart, Lung, and Blood Institute
  • Konung Gustaf V:s and Drottning Victorias Stiftelse
  • NHLBI NIH HHS
  • National Academic Infrastructure for Supercomputing in Sweden
  • Bern Center of Precision Medicine Lighthouse Grant
  • H2020 European Research Council

Zitieren

APA

Hiniesto-Iñigo, I., Sridhar, A., Louradour, J., De la Cruz, A., Lundholm, S., Jauregi-Miguel, A., Giannetti, F., Sala, L., Odening, K. E., Larsson, H. P., Ottosson, N. E., & Liin, S. I. (2025). Rescue of loss‐of‐function long QT syndrome‐associated mutations in K V 7.1/KCNE1 by the endocannabinoid N‐arachidonoyl‐L‐serine (ARA‐S). British Journal of Pharmacology. https://doi.org/10.1111/bph.70008

Vancouver

Hiniesto-Iñigo I, Sridhar A, Louradour J, De la Cruz A, Lundholm S, Jauregi-Miguel A, et al. Rescue of loss‐of‐function long QT syndrome‐associated mutations in K V 7.1/KCNE1 by the endocannabinoid N‐arachidonoyl‐L‐serine (ARA‐S). British Journal of Pharmacology. 2025. doi:10.1111/bph.70008

BibTeX
@article{HiniestoIigo2025,
  author = {Hiniesto-Iñigo, Irene and Sridhar, Akshay and Louradour, Julien and De la Cruz, Alicia and Lundholm, Siri and Jauregi-Miguel, Amaia and Giannetti, Federica and Sala, Luca and Odening, Katja E and Larsson, H Peter and Ottosson, Nina E and Liin, Sara I},
  title = {Rescue of loss‐of‐function long QT syndrome‐associated mutations in K V 7.1/KCNE1 by the endocannabinoid N‐arachidonoyl‐L‐serine (ARA‐S)},
  journal = {British Journal of Pharmacology},
  year = {2025},
  doi = {10.1111/bph.70008}
}
Kostenlos starten →